Background. The impact of hepatitis B virus (HBV) genotypes B and C on the clinical, immunologic, and virologic outcomes of human immunodeficiency virus (HIV)-infected patients with chronic HBV infection remains largely unknown.
Hepatitis B virus (HBV) infection is an important cause of chronic hepatitis, cirrhosis, and hepatocellular carcinoma (HCC) worldwide [1] . Due to shared modes of transmission, coinfection with HBV and human immunodeficiency virus (HIV) is not uncommon [2] . Previous studies have shown that HIV coinfection accelerates HBV-related liver damage, leading to earlier cirrhosis and end-stage liver disease [2, 3] . On the other hand, the presence of HBV coinfection complicates the management of HIV and increases the morbidity and mortality of HIV-infected patients.
HBV is a DNA virus that replicates by reverse transcription of the pregenomic RNA using a viralencoded polymerase. The lack of proofreading ability of the viral polymerase results in wide virus sequence heterogeneity [1] . Based on an intergroup divergence of at least 8% in the entire viral genome, HBV can be classified into at least 8 major genotypes (A-H) [4, 5] . The distribution of genotypes has been found to vary across geographic regions [5] . For example, genotypes A, D, and E prevail in northern Europe, North America, the Middle East, Africa, and India, while genotypes B and C are prevalent in Asia, particularly in China, Japan, Korea, Taiwan, and Vietnam [5] .
Clinical studies have demonstrated the association between HBV genotypes with clinical and therapeutic outcomes in HBV-monoinfected patients [6] [7] [8] . For example, infection with HBV genotype C is more closely associated with active liver disease and increased risk for HCC than is infection with genotype B [8] , whereas infection with genotype D is more likely to cause severe liver disease than is infection with genotype A [7, 9] . Baseline hepatitis B e antigen (HBeAg) positivity has been shown to be significantly lower in patients infected with genotype D than in those with genotype A (36% vs 80%, respectively; P , .0001) [7] ; however, the rate of sustained remission after seroconversion was higher in patients with genotype A than in those with genotype D (55% vs 32%, respectively; P , .01). Patients infected with genotype C have a lower rate of spontaneous HBeAg seroconversion than those with genotype B (27% vs 47%, respectively; P 5 .025) [10] . Seroconversion of HBeAg related to emergence of HBV mutants (precore G1896A mutation or basal core promoter [BCP] A1762T and G1764A mutations) is more frequently observed in patients infected with genotypes D and B than in those with genotypes A and C [6] [7] [8] . The higher frequency of precore G1896A mutation in genotypes D and B than in genotypes A and C might partly explain why persistent activity is more frequent in patients infected with genotypes B and D [10] [11] [12] .
In previous studies conducted in patients with HIV and HBV coinfection, patients with HBV genotype A were noted to have higher baseline plasma HBV DNA loads [13] , a higher frequency of HBeAg positivity [14] , and better HBV DNA suppression while on anti-HBV therapy than patients with other genotypes (D, E, F, and G) [15, 16] . Precore or BCP mutants were more frequently seen in patients with genotype D than in those with genotype A (63% vs 18%, respectively; P , .01) [14] . However, little is known about the impact of HBV genotypes B and C on the HBV and HIV coinfected population. In this study, we investigated the impact of HBV genotypes B and C on the clinical and therapeutic outcomes in patients with HBV and HIV coinfection who received lamivudine-containing highly active antiretroviral therapy (HAART) in Taiwan, where chronic HBV infection is hyperendemic [17, 18] .
METHODS

Patients and Setting
This study was a prospective, observational cohort study, in which HIV-infected patients who were positive for hepatitis B surface antigen (HBsAg) for at least 6 months (chronic HBV infection) and received HAART were enrolled between 1 January 1997 and 31 December 2008. HAART, which includes lamivudine in the recommended regimens according to the local treatment guidelines, was introduced to Taiwan in April 1997, and all patients were offered free access to HIV care and HAART at designated hospitals around Taiwan. Tenofovir was not available during the study period, and adefovir and entecavir were not reimbursed by the National Health Insurance of Taiwan until September 2006  and August 2008, respectively. The study conformed to the provisions of the 1975 Declaration of Helsinki and was approved by the institutional review board of the hospital (NTUH-9261700889).
Laboratory Tests and Radiographic Investigations
After initiation of HAART, patients were followed every 2-4 weeks and subsequently every 3 months for clinical and laboratory evaluations for 1 year; after the first year, most patients were followed every 3 months, and the laboratory evaluation was performed every 6 months. All available blood samples were archived for determinations of serum HBV DNA levels.
Plasma HIV RNA load (PVL) was quantified using reversetranscriptase polymerase chain reaction (PCR) (Roche Amplicor, version 1.5, Roche Diagnostics) with a lower detection limit of 50 (1.70 log 10 ) copies/mL, and CD4 cell counts were determined using FACFlow (BD FACSCalibur; Becton Dickinson). Serologies for HBV (HBsAg, anti-HBs, HBeAg, anti-HBe, total immunoglobulin G against HBV core antigen [anti-HBc]), hepatitis C virus (HCV) (anti-HCV), and hepatitis D virus (anti-HDV) were assayed with the use of commercial kits (Abbott Laboratories). HBV DNA loads and genotypes were determined with the use of the real-time PCR-based, single-tube assay as previously described [19] . Six genotypes (A-F) could be identified. The polymerase gene containing tyrosine, methionine, aspartate, and aspartate (YMDD) motif (rtM204I/V) of patients with detectable HBV DNA was amplified using a PCR assay. The presence of YMDD mutant was confirmed by direct sequencing using an automatic ABI-DNA sequencer (Model 377 A; Applied Biosystems). HBV DNA level was determined at enrollment, annually, and at the end of this study and when clinically indicated (eg, hepatitis flare).
The BCP region was directly sequenced as previously described [20] . In brief, the BCP region was first amplified by nested PCR assays. The PCR products were then directly sequenced using an automatic ABI DNA sequencer (Model 377A; Applied Biosystems), with emphasis on nucleotides 1762 and 1764. The assay could detect the presence of the minor group (.20% of the whole viral population).
Assessment of Virologic, Immunologic, and Clinical Responses to HAART
Virologic response to HAART was assessed by the proportion of patients achieving a PVL,400 copies/mL obtained at 6, 12, and 24 months of HAART. Immunologic response was assessed by the changes of CD4 count from baseline to 12 and 24 months of HAART. Hepatitis flare was defined as at least a 5-fold elevation of serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels (normal upper limit of AST and ALT, 31 and 41 U/L, respectively); and hyperbilirubinemia as a total bilirubin $2.0 mg/dL (normal upper limit, 1.0 mg/dL) without evidence of hemolysis. Hepatic decompensation was defined according to Child-Pugh criteria [21] . HAART was defined as the combination of 2 nucleoside reverse-transcriptase inhibitors plus protease inhibitors or nonnucleoside reverse-transcriptase inhibitors. Cirrhosis was documented by liver histology or the presence of coarse echogenicity and irregular liver surface accompanied with splenomegaly as demonstrated by abdominal sonography or computed tomography.
Statistical Analysis
All statistical analyses were performed using SPSS 18.0 software (SPSS Inc). Categorical variables were compared using v 2 or Fisher exact test, and a 2-sample t test was used for the comparisons of continuous variables. Noncategorical variables were compared using the Wilcoxon rank-sum test. The significance level was set at .05, and all P values were 2-tailed. Multivariate Cox regression was used to evaluate the potential role of age, sex, risk factors for HIV infection, baseline and increment of CD4 count, initial PVL and HBV DNA load, HBV genotype, duration of lamivudine therapy, anti-HCV and anti-HDV positivity, and HBe antigenemia for the events of hepatitis flares, development of lamivudine resistance, and mortality. The probabilities of outcomes of interest stratified by genotypes B and C were estimated using Kaplan-Meier estimates and compared using logrank test. The survival duration of patients was estimated from the date of enrollment to death or the end of this observational study on 31 December 2010, whichever occurred first.
RESULTS
During the study period, 218 HIV-infected patients with chronic HBV coinfection were identified, and 152 patients c HBsAg and HBeAg were tested in 72 patients from the genotype B group and 36 from the genotype C group at the last visit or end of the study.
d Basal core promotor T1762/A1764 mutation was tested in 70 patients from the genotype B group and 39 from the genotype C group.
e The genotypic resistance mutations to lamivudine (M204V/I) were YVDD (n 5 21), YIDD (n 5 6), and YVDD/YIDD (n 5 3) in patients with HBV genotype B, and YVDD (n 5 2) and YIDD (n 5 4) in patients with HBV genotype C. f The data of plasma HIV viral load were available for 68 and 40 of patients with genotypes B and C at 6 months, 61 and 38 at 12 months, and 41 and 29 at 24 months, respectively. The median baseline serum HBV DNA level was 4.87 log 10 copies/mL (IQR, 3.74-6.81 log 10 ). There were no significant differences between the 2 groups in terms of age, sex, risk for HIV transmission, baseline CD4 count and PVL, presence of opportunistic infection, and baseline aminotransferase levels, HBeAg positivity, and HBV DNA load (Table 1 ). There were no differences in frequency of laboratory follow-up between the 2 groups during the study period; the median number of tests was 9 in genotype B group and 8 in genotype C group (P 5 .82).
HIV/AIDS
The patients were followed for a median duration of 2.80 years (IQR, 1.66-5.91 years) while undergoing lamivudinecontaining HAART. Patients infected with HBV genotype B had a higher risk of hepatitis flares (43.8% vs 26.5%, respectively; P 5 .04), liver disease-related deaths (9.4% vs 0%, respectively; P 5 .03), HBeAg seroconversion (61.5% vs 25.0%, respectively; P 5 .03), and development of lamivudine resistance (31.3% vs 12.2%, P , .0001) than those with genotype C (Table 2) . Although patients with HBV genotype B had higher rates of hyperbilirubinemia, cirrhosis, and HCC than those with genotype C, the differences were not statistically significant. There was no difference in the virologic response of HBV to lamivudine or virologic and immunologic responses to HAART between the 2 groups ( BCP sequences could be characterized in 109 patients with HBV viremia. The BCP A1762T/G1764A mutant was found in 20 patients (18.3%). The frequency of BCP mutant was comparable between patients with genotypes B and C (17.1% vs 20.5%, respectively; P 5 .66). Of 16 patients with HBV genotype B who had HBeAg seroconversion, 7 (43.8%) developed acute hepatitis flares, 3 (18.8%) died from liver-related disease, and 6 (37.5%) developed lamivudine resistance, indicating the persistence of viral activity. These results were similar to those of patients who did not have HBeAg seroconversion (all comparisons, P . .10) (data not shown).
Genotypic resistance to lamivudine was investigated in 43 patients who experienced rebound of plasma HBV DNA, and rtM204V/I was found in 36 (83.7%). The median time to development of lamivudine resistance was 5.02 years (IQR, 2.20-6.71 years). Lamivudine-resistant mutants tended to occur earlier in patients with HBV genotype B than in those with genotype C (median, 4.72 vs 5.63 years, respectively; P 5 .09). This interval was estimated by taking into account the time from initial lamivudine exposure to the first sample that demonstrated lamivudine genotypic resistance. The mutation patterns of the 36 HBV DNA samples included 21 YVDD mutations, 6 YIDD, and 3 YVDD/YIDD in patients with genotype B, and 2 YVDD and 4 YIDD in those with genotype C. In brief, patients with genotype B tended to have a higher frequency of YVDD mutation than those with genotype C (80% vs 33.3%, respectively; P 5 .08). Of 42 patients with available HBV DNA data preceding hepatitis Compared to patients infected with HBV genotype C, those with genotype B had a higher risk of developing hepatitis flare (AHR, 4.13 [95% CI, 2.87-5.39]; log-rank P 5 .01) and lamivudine genotypic resistance (AHR, 8.67 [95% CI, 6.37-10.98]; log-rank P 5 .001) during the follow-up (Figures 2 and 3 ). There were no mortality differences between patients coinfected with HBV genotypes B and C (log-rank P 5 .11) (Figure 4 ).
DISCUSSION
In this study, we found that HBV genotypes B and C were the only HBV genotypes in HBV and HIV-coinfected Taiwanese patients. Patients with HBV genotype B coinfection were at higher risks of developing hepatitis flares, liver disease-related deaths, HBeAg seroconversion, and lamivudine resistance mutations than those with genotype C coinfection.
In HBV-monoinfected patients receiving lamivudine, the annual rates of HBeAg seroconversion were found to be 18% in patients with genotype B and 10% in patients with genotype C [22] , which is comparable to our findings in HIV-infected patients with genotype B (61% HBeAg seroconversion) and genotype C (25%) infection after a 3-year course of lamivudine therapy. In line with a previous study on HBV-monoinfected patients [23] , there were no differences in the reduction of HBV DNA loads between HBV genotypes B and C in our HIV-infected patients, which suggests that once lamivudinecontaining HAART is initiated, HIV has little impact on the virologic responses of patients infected with genotypes B and C.
Compared with HIV-infected patients with HBV genotype C coinfection who received lamivudine-containing HAART, those with genotype B coinfection had higher rates of hepatitis flare, HBeAg seroconversion, emergence of lamivudine genotypic resistance, and liver disease-related deaths. In contrast, HBV genotype C has been reported to be associated with more severe liver disease and risk of HCC than has genotype B in patients with HBV monoinfection [8, 9, 24] . The reasons for the discrepant findings are unclear, but may be related to age when HBV transmission occurred, HIV-related immunosuppression, and emergence of drug-resistant mutations. Additional information of comparison between HBV genotypes B and C were shown in supplementary table.
The immune-mediated damage during the immunoclearance phase of chronic HBV infection may be associated with a higher rate of HBeAg seroconversion, hepatitis exacerbation flares, and hepatic decompensation in patients with genotype B infection than in those with genotype C infection [25] . Similar to other studies on HBV-monoinfected patients [25, 26] , our study showed that patients with genotype B coinfection had a higher rate of HBeAg seroconversion than those with genotype C coinfection. These findings suggest that HBV genotype B may be more immunogenic than genotype C and thus cause more severe immune-mediated liver cell damage.
Mutations in the BCP region of the HBV genome are commonly seen in patients with high-level viremia who are negative for HBeAg [11, 12, 27] . The genome of HBV genotype D is more prone to evolution to BCP mutation compared with genotype A [27] , even in patients with HIV coinfection [14] . These virologic characteristics may explain a significantly higher prevalence of HBeAg-negative chronic HBV infection in patients with genotype D than in those with genotype A. In the HBVmonoinfected population, patients with genotype C have a higher prevalence of BCP mutation than those with genotype B, which may increase the risk of liver disease progression and development of HCC [28] . However, we failed to reproduce these findings in coinfected patients due to the relatively small patient number and short observation in this study. Although we did not assay precore 1896 mutation, we previously have shown that 74% of HBV genotype B carriers who were negative for HBeAg had a G-to-A change at nucleotide 1896 (G1896A mutation) that completely abolishes the production of HBeAg [29] . The higher frequency of precore 1896 mutation in genotype B than in genotype C might partly explain why persistent activity was more frequent in patients with genotype B infection, either in patients with positive anti-HBe at diagnosis or after seroconversion to anti-HBe in those with HBeAg at baseline.
Compared with HBV-monoinfected patients, HBV and HIVcoinfected patients develop resistance-conferring mutations more rapidly after prolonged lamivudine therapy, at an annual rate of 20% [30, 31] . Previous studies have shown that HBV and HIV-coinfected patients with HBV genotype A had an earlier emergence and a higher frequency of lamivudine resistance than those with genotype D [14, 32] . A recent study in HBVmonoinfected patients also showed that genotype B was significantly associated with a higher frequency of lamivudine resistance compared with genotype C during the first year of therapy (odds ratio, 8.27; P 5 .004) [20] . Similarly, we also found a significantly higher frequency of lamivudine resistance that emerged earlier in HIV-infected patients with genotype B coinfection compared with those with genotype C coinfection, not just during the first year and 3 years of therapy (13.5% vs 2%, respectively; P 5 .06; and 31.3% vs 12.2%, respectively; P , .0001, respectively). In this study, a higher rate of spontaneous HBeAg seroconversion and earlier development of lamivudine resistance mutations in genotype B than in genotype C might explain why HIV-infected patients with genotype B coinfection had more hepatitis flares during lamivudine therapy. Therefore, more frequent monitoring of viral load or genotypic resistance might be needed for patients with HBV genotype B infection receiving HAART that contains only lamivudine for HBV.
Our study has several limitations. First, the patient number is small, and we did not include patients not undergoing HAART or those receiving HAART that did not contain lamivudine. Second, HBV DNA levels were usually determined when biochemical breakthrough or hepatic flares occurred. The lag between emergence of drug-resistant mutants and detection of HBV DNA level or elevated aminotransferases was foreseeable.
In summary, HBV genotype B is the most predominant genotype in HBV and HIV-coinfected Taiwanese patients, and patients with genotype B coinfection are more likely to experience acute exacerbations of hepatitis, HBeAg seroconversion, lamivudine resistance, and liver disease-related death than those with genotype C coinfection when they receive HAART containing lamivudine as the only active agent against HBV.
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